reducing CV death, nonfatal MI, HHF and end-stage kidney disease [66]. According to the same analysis, finerenone is likely to reduce HHF, end-stage renal disease and possibly CV death [66]. Only GLP-1 RAs were found to reduce nonfatal stroke and SGLT2is were found to be superior ...
ccRCC is substantially insensitive to current therapies, and the efficacy of clinical treatment is dependent on the dissemination stage of the tumor. The present study shows that CPTH2 is able to induce apoptosis and decrease the invasiveness of a ccRCC cell line through the inhibition of KAT3B....
is one of the most common monogenetic disorders and the leading genetic cause of end-stage renal disease (ESRD) in the United States1,2,3. This condition is characterized by the presence of numerous fluid-filled cysts originating from renal tubules. Excessive proliferation of mutant epithelial...
“Following promising activity in the dose-escalation stage, I am further encouraged by the anti-tumor activity observed in the monotherapy expansion cohort suggesting that zanzalintinib may be an effective therapy following disease progression after prior treatments,” said Sumanta Pal, M.D., Clini...
Candidate genes from a defined disease pathway (renal necrosis/cell death) that possessed the following criteria were selected for further analyses: (1) the absolute gene expression level should be markedly induced; (2) the trend of gene expression should be consistent throughout the course of ...